Abstract:Background To characterize the microbiome in early-onset colorectal cancer (aged <50, EOCRC) and late-onset CRC (aged ≥50, LOCRC) patients. Methods 460 CRC patients (167 EOCRC) were recruited in Guangzhou, and deep shotgun metagenomic sequencing was applied to stool and saliva samples. De novo genome assembly, binning, inStrain, StrainPhlAn and MetaPhlAn analyses were performed. Stool metagenomes from a Fudan study (Yang et al., 2021) consisting of 50 EOCRC, 50 LOCRC and 100 age-matched controls were also included. Results Despite age being a determining factor for the gut microbiome, our analyses found limited associations between the gut microbiome and age in CRC. Well-known CRC-associated taxa (IDDF2024-ABS-0170 Figure 1. CRC-associated taxa and genes enriched in both EOCRC and LOCRC (a)) and genes (IDDF2024-ABS-0170 Figure 1. CRC-associated taxa and genes enriched in both EOCRC and LOCRC (b)) were consistently enriched in both EOCRC and LOCRC. In the strain-level analysis on Fusobacterium nucleatum (Fn), we identified two Fn subspecies animalis Clades (Fna C1 and C2), with Fna C2 as the dominant strain (IDDF2024-ABS-0170 Figure 2. Distribution of Fna C1 and Fna C2 in CRC patients (a)). This observation is in line with a Nature study (Zepeda-Rivera et al., 2024). We confirmed that fadA abundance did not differ in patients carrying either Fna C1 or C2 (IDDF2024-ABS-0170 Figure 2. Distribution of Fna C1 and Fna C2 in CRC patients (b)). More importantly, we found that both the abundances of Fna C1 and C2 were associated with mismatch repair and HER2 expression status (IDDF2024-ABS-0170 Figure 2. Distribution of Fna C1 and Fna C2 in CRC patients (c,d)), suggesting their potential roles in CRC clinical outcomes. We identified two distinct Bacteroides fragilis (Bf) strain clusters with high genome-wide similarity to the reference genomes of strain NCTC 9343 and Q1F2 respectively (IDDF2024-ABS-0170 Figure 3. Two distinct Bf strain clusters in CRC patients (a)). Intriguingly, the abundance and prevalence of Bf toxin gene bft were significantly higher in patients with strain NCTC9343 than Q1F2 (IDDF2024-ABS-0170 Figure 3. Two distinct Bf strain clusters in CRC patients (b)). Only one strain cluster was identified for Escherichia coli (Ec) (IDDF2024-ABS-0170 Figure 4. Correlations between Ec and pks genomic island (a)). A positive correlation between pks genomic island and Ec was observed in the Guangzhou cohort, but no correlation in the Fudan cohort, indicating population heterogeneity. Lastly, we found that the baseline compositions of gut and oral microbiome had remarkable differences between patients with different responses in anti-PD1 treatment (IDDF2024-ABS-0170 Figure 5. Gut and oral microbes associated with anti-PD1 treatment response). Conclusions Our results highlight striking similarities in microbial signatures between EOCRC and LOCRC, emphasizing the important roles of microbiome in CRC biology and treatment.

Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer

Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients

Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer

Colorectal cancer-associated bacteria are broadly distributed in global microbiomes and drivers of precancerous change

Integrated Analysis of Colorectal Cancer Reveals Cross-Cohort Gut Microbial Signatures and Associated Serum Metabolites

Microbiome and metabolic features of tissues and feces reveal diagnostic biomarkers for colorectal cancer

Disease-associated Gut Microbiome and Critical Metabolomic Alterations in Patients with Colorectal Cancer

Microbiome analysis reveals universal diagnostic biomarkers for colorectal cancer across populations and technologies

Abstract 2807: Distinctive microbiome signatures in colorectal cancer: A comparative metagenomic analysis

IDDF2021-ABS-0210 Altered Gut Metabolites and Bacterial Interactions Are Implicated in Colorectal Carcinogenesis and Can Detect Precancerous and Cancerous Lesions

Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer

Colorectal cancer-specific microbiome in peripheral circulation and cancer tissues

Gut Microbiota Signatures in Tumor, Para-Cancerous, Normal Mucosa, and Feces in Colorectal Cancer Patients

Metaproteomics characterizes human gut microbiome function in colorectal cancer

Alterations of the Gut Microbiome and Fecal Metabolome in Colorectal Cancer: Implication of Intestinal Metabolism for Tumorigenesis

IDDF2024-ABS-0170 Metagenomic Analyses Highlight Strain-Level, Age-Independent and Immunotherapy-Associated Microbial Signatures in Colorectal Cancer

IDDF2023-ABS-0250 Comprehensive Analyses of Microbiome and Metabolism Reveal Liver Metastasis-Specific Signature in Colorectal Cancer

Tumor-associated microbiome features of metastatic colorectal cancer and clinical implications

Metagenomic and Targeted Metabolomic Analyses Reveal Distinct Phenotypes of the Gut Microbiota in Patients with Colorectal Cancer and Type 2 Diabetes Mellitus

Taxonomic and functional profiling of fecal metagenomes for the early detection of colorectal cancer

Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers